Syndax wins U.S. approval for leukemia treatment

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced leukemia.

The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market.

Revuforj was approved to treat adults and children with relapsed or refractory leukemias that have a genetic “rearrangement” called KMT2A. This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high relapse rates and survival of less than a year.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Ohio Voters Back Constitutional Right to Abortion

Ohio voters approved a constitutional amendment protecting access to abortion on Tuesday. The amendment also protects access to other types of reproductive healthcare, including contraception,

November 9, 2023

FDA says all versions of Novo’s GLP-1 weight loss drugs are now available

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 31, 2024

Study links cord blood lipid levels to early ADHD and autism symptoms

The relationship between ADHD and autism spectrum disorder (ASD).

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.